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Design: Retrospective cohort study of RCT protocols approved by six research ethics committees in Switzerland,
Germany, and Canada between 2000 and 2003. We compared protocols to corresponding publications, which were identi-
ﬁed through literature searches and investigator surveys.
Results: Of the 173 cancer trials, 90 (52%) speciﬁed QoL outcomes in their protocol, 2 (1%) as primary and 88 (51%) as
secondary outcome. Of the 173 trials, 35 (20%) reported QoL outcomes in a corresponding publication (4 modiﬁed from
the protocol), 18 (10%) were published but failed to report QoL outcomes in the primary or a secondary publication, and 37
(21%) were not published at all. Of the 83 (48%) trials that did not specify QoL outcomes in their protocol, none subsequent-
ly reported QoL outcomes. Failure to report pre-speciﬁed QoL outcomes was not associated with industry sponsorship
(versus non-industry), sample size, and multicentre (versus single centre) status but possibly with trial discontinuation.
Conclusions: About half of cancer trials speciﬁed QoL outcomes in their protocols. However, only 20% reported any QoL
data in associated publications. Highly relevant information for decision making is often unavailable to patients, oncologists,
and health policymakers.
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introduction
Information about the impact of cancer treatments on patients’
quality of life (QoL) is of paramount importance to patients and
treating oncologists. Lack of QoL outcomes complicates decision
making, especially in palliative situations when the expected sur-
vival beneﬁt of a speciﬁc therapy may be small but its impact on
QoL essential. Therefore, major funding and regulatory agencies,
policymakers, and patient organizations increasingly demand
measurement of QoL outcomes in clinical studies [1, 2].
In spite of the availability of valid instruments such as the
European Organization of Research and Treatment of Cancer
Quality of Life Questionnaire (EORTC QLQ-C30) or the
Functional Assessment of Cancer Therapy (FACT) [3, 4], publi-
cations of randomized clinical trials (RCTs) involving cancer
patients often do not report on QoL outcomes. For instance, only
41% of advanced-stage lung cancer trials published between 2006
and 2008 reported a QoL outcome [5]. Instead, cancer trials typ-
ically focus on survival or tumour size as their primary outcome
[5–7], a trend that has constantly increased over time [6, 7]. In
addition, reporting quality of QoL outcomes was found to be
highly variable [8, 9], and recent initiatives have provided guid-
ance in an effort to improve and harmonize reporting practices
[10, 11].
However, the magnitude of two other fundamental problems,
the non-speciﬁcation of QoL as an outcome and failure to
report collected QoL data, is unknown. If cancer trials do not
specify QoL as an outcome or fail to report collected QoL data,
crucial information is not available for decision making and the
risk of misguidance due to selective reporting increases.
The objective of this study was to systematically compare the
planning of QoL outcomes in RCT protocols involving cancer
patients with subsequent reporting in publications. In addition,
we explored risk factors for non-reporting of planned QoL
outcomes.
methods
study design
This is an ancillary analysis of a large retrospective cohort of RCTs that were
approved by six research ethics committees (RECs) in Switzerland (Basel,
Lausanne, Zurich, and Lucerne), Germany (Freiburg), and Canada (Hamilton)
between 2000 and 2003 [12–15]. All RECs but one are responsible for human
research in large university centres and additional hospitals in their respective
catchment areas; one (Lucerne) covers an academic teaching hospital. As a con-
venience sample, we approached them through existing contacts.
In the present study, we included RCT protocols that involved patients
with solid or haematological malignancies. We excluded protocols of RCTs
that: (i) compared only different doses or routes of administration of the
same drug (early dose-ﬁnding studies), (ii) were never started, or (iii) were
still on-going as of February 2014. We included full peer-reviewed journal
publications of corresponding RCT protocols and excluded research letters,
letters to the editor, or conference abstracts.
We conducted comprehensive searches of electronic databases to locate
any associated publications. In addition, we hand-searched the ﬁles of RECs,
and the RECs sent survey questionnaires to study investigators in case of
missing information. Our search strategy is reported elsewhere [12]. Two
investigators (BK and SS) searched independently and in duplicate for sec-
ondary publications reporting additional QoL results. The last update of the
search was carried out in February 2014.
deﬁnitions
We accepted at face value all QoL outcomes reported as such by investigators
of individual trials. We included QoL outcomes irrespective of whether they
were measured by multidimensional questionnaires (e.g. EORTC QLQ-C30)
or by direct valuation (e.g. visual analogue scale) and whether they were
generic or disease speciﬁc.
We assessed RCT protocols for industry or investigator sponsorship using
the following criteria: the protocol clearly named the sponsor, displayed a
company or institution logo prominently, mentioned afﬁliations of protocol
authors, included statements about data ownership or publication rights,
or included statements about full funding by industry or public funding
agencies [12, 13].
We considered an RCT discontinued if the investigators indicated discon-
tinuation with a reason in their correspondence with the REC, in a journal
publication, or in their response to our survey. If we could not elucidate the
reason for RCT discontinuation or if poor participant recruitment was men-
tioned, we used a pre-speciﬁed cut-off of <90% of achieved target sample
size to classify discontinuation [12, 13].
data extraction
Investigators trained in research methodology independently extracted data
from eligible RCT protocols and from correspondence between the RECs
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and the local investigators that was documented in the REC ﬁles. Thirty-
nine percent of protocols from cancer RCTs were extracted in duplicate as
an initial calibration process to maximize the consistency of data extraction
across reviewers; all corresponding publications were extracted in duplicate.
Disagreements were resolved by consensus or by third-party adjudication.
Speciﬁcally for this project, two oncologists (KC and BK) independently
assessed the pairs of protocols and corresponding publications for agreement
with respect to the type of QoL instrument(s). For each RCT, they judged
independently whether the QoL results were: (i) reported for all subdomains
of all speciﬁed instruments, (ii) reported but not for all subdomains or
instruments, (iii) reported but using completely different instruments than
speciﬁed, or (iv) not reported at all. In addition, the same two oncologists in-
dependently judged the aim of therapy (i.e. palliative, curative, mix, treating
side-effects of cancer therapy, unclear) and stage of malignancy (i.e. meta-
static, advanced, localized, mix, unclear). They resolved disagreements by
consensus or by third-party adjudication.
statistical analysis
For binary data, we summarized results as frequencies and proportions and
for continuous data as medians and interquartile ranges (IQRs). We present
the results as proportions and associated 95% conﬁdence intervals (95%
CIs) using the Jeffreys method [16]. We used the χ2 test to explore differ-
ences in proportions. Using complete case multivariable logistic regression,
we tested the association between the dependent variable ‘reporting of any
QoL outcomes’ and the following four independent variables: (i) discontin-
ued RCT (versus completed); (ii) investigator sponsorship (versus industry);
(iii) single-centre status (versus multicentre); and (iv) sample size (continu-
ous, in increments of 100). These variables are known to be associated with
non-publication of RCTs [13], and industry sponsorship is known to be
associated with selective outcome reporting [17]. Therefore, we hypothesized
that these variables might also be associated with failure to report pre-
speciﬁed QoL outcomes. We limited our regression model to the subset of
trials that pre-speciﬁed a QoL outcome in their protocol. We carried out sen-
sitivity analyses using (i) the alternative outcome deﬁnition ‘reporting of
QoL outcomes as pre-speciﬁed in protocol’ and the same independent vari-
ables and (ii) multiple imputations for missing information about trial dis-
continuation (missing in seven RCTs) [18]. We expressed associations as
odds ratios (ORs) with 95% CIs and considered two-sided P≤ 0.05 as signiﬁ-
cant. We used R version 3.1.0 (www.r-project.org) for all analyses.
results
protocol and publication characteristics
Of 894 RCT involving patients, 173 (19%) enrolled patients
with cancer (Figure 1). Most cancer trials were multicentre
RCTs investigating palliative drug treatments in patients with
solid malignancies, half of the trials were industry-sponsored
(87, 50%), and one-third were discontinued (50, 34%). The
most frequent reason for discontinuation was poor recruitment
(22, 13%) (Table 1).
Of the 173 cancer trials, 108 (62%) were subsequently pub-
lished as full journal article; 52 (30%) cancer RCTs were not
published at all, and 13 (8%) were published but not as full
journal articles. Publication dates ranged between 2003 and
2013, with a median at 2007. The median time between ethical
approval and ﬁrst full journal publication was 5.7 years (IQR,
4.5–7.8 years, range 0.7–12.1 years).
planning of QoL outcomes
The most frequently speciﬁed primary outcomes were survival
and tumour response (Table 1). Ninety of 173 (52%, 95% CI
289 Basel
Included Excluded
123 enrolling healthy volunteers
721 not involving cancer patients
53 never started (including 4 cancer RCTs)
10 still ongoing (including 3 cancer RCTs)
1080 RCT protocols approved by six research
ethics committees
894 RCT protocols involving patients
173 RCT protocols involving cancer patients
90 specifying QoL
outcomes
83 not specifying QoL
outcomes
55 published as full
journal article
0 publications
reporting QoL
outcomes
53 published as full
journal article
35 publications
reporting QoL
outcomes
418 Freiburg
198 Hamilton
192 Lausanne
38 Lucerne
54 Zürich
Figure 1. Study selection. RCT, randomized clinical trial; REC, research ethics committee; QoL, quality of life.
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45% to 59%) cancer trial protocols reported the measurement of
QoL outcomes. QoL was deﬁned as the sole primary outcome in
one protocol, as a co-primary outcome in a second, and as a sec-
ondary outcome in 88 protocols. The remaining 83 (48%, 95%
CI 41% to 55%) RCTs failed to specify a QoL outcome in their
protocol (and none of these reported a QoL outcome in subse-
quent publications). The proportion of RCT specifying QoL
outcomes did not differ signiﬁcantly across RECs (supplemen-
tary Table 1, available at Annals of Oncology online).
Most RCT protocols (57, 63%) speciﬁed one QoL instrument;
the remaining speciﬁed two (26%) or three instruments (3%), or
the number of instruments was unclear (8%). The most
common QoL instruments to be used were the EORTC QLQ
(core questionnaire or modules) in 47 of 90 RCTs (52%), the
FACT (core questionnaire or modules) in 19 RCTs (21%), and
the EuroQoL-5D (EQ-5D) in 5 RCTS (6%). Other instruments
were used in 9 RCTs (10%), and instruments were not speciﬁed
in 15 (17%).
Table 1. Characteristics of cancer RCTs
Total
(N = 173)
Investigator-sponsored
(N = 86)
Industry-sponsored
(N = 87)
Sample size, median (IQR) 318 (132–685) 330 (200–624) 300 (125–690)
Multicentre study 168 (97%) 83 (97%) 85 (98%)
Superiority design 141 (82%) 74 (86%) 67 (77%)
Haematologic malignancy 40 (23%) 29 (34%) 11 (13%)
Solid malignancy 133 (77%) 57 (66%) 76 (87%)
Metastatic stage 81 (47%) 27 (31%) 54 (62%)
Advanced stage 25 (15%) 12 (14%) 13 (15%)
Localized stage 3 (2%) 2 (2%) 1 (1%)
Mix of stages 12 (7%) 6 (7%) 6 (7%)
Unclear stage(s) 12 (7%) 10 (12%) 2 (2%)
Type of cancer (only categories ≥5%)
Breast cancer 33 (19%) 12 (14%) 21 (24%)
Non-small-cell lung cancer 16 (9%) 2 (2%) 14 (16%)
Colorectal cancer 11 (6%) 3 (4%) 8 (9%)
Non-Hodgkin lymphoma 9 (5%) 6 (7%) 3 (3%)
Pancreatic cancer 8 (5%) 3 (4%) 5 (6%)
Drug intervention 164 (95%) 78 (91%) 86 (99%)
Therapy intent
Palliative 112 (65%) 49 (57%) 63 (72%)
Curative 35 (20%) 22 (26%) 13 (15%)
Mix 2 (1%) 2 (2%) 0
Treating side-effects of cancer therapy 16 (9%) 7 (8%) 9 (10%)
Unclear 8 (5%) 6 (7%) 2 (2%)
Type of primary outcome
Overall survival 49 (28%) 23 (27%) 26 (30%)
Progression- or disease-free survival 51 (30%) 25 (29%) 26 (30%)
Tumour response 23 (13%) 11 (13%) 12 (14%)
Symptom control 17 (10%) 8 (9%) 9 (10%)
Quality of life 2 (1%) 0 2 (3%)
Other 25 (14%) 15 (17%) 10 (11%)
Not specified 6 (3%) 4 (5%) 2 (2%)
Trial completion status
Completed 105 (61%) 51 (59%) 54 (62%)
Discontinued 59 (34%) 31 (36%) 28 (32%)
Poor recruitment 22 (13%) 13 (15%) 9 (10%)
Futility 15 (9%) 6 (7%) 9 (10%)
Administrative 6 (4%) 2 (2%) 4 (5%)
Harm 6 (4%) 3 (4%) 3 (3%)
Benefit 5 (3%) 5 (6%) 0
External evidence 2 (1%) 1 (1%) 1 (1%)
Other reason 2 (1%) 1 (1%) 1 (1%)
Unclear reason 1 (1%) 0 1 (1%)
Completion status unclear 9 (5%) 4 (5%) 5 (6%)
RCT, randomized clinical trial; IQR, interquartile range.
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The frequency of planning of QoL outcomes did not differ
signiﬁcantly between investigator-sponsored (47/86, 55%) and
industry-sponsored (43/87, 49%) RCTs (P = 0.49). Of 112
RCT protocols that investigated palliative treatments, 65 (57%)
planned to measure QoL.
reporting of QoL outcomes
Of the 173 cancer RCTs, 35 (20%, 95% CI 15% to 27%) reported
QoL outcomes in a corresponding publication (including 6 sec-
ondary publications); of these, 31 (18%, 95% CI 13% to 24%)
reported QoL outcomes exactly as speciﬁed and 4 (2%, 95% CI
1% to 5%) modiﬁed reporting from the protocol (3 reported only
one of two speciﬁed instruments; 1 reported two completely dif-
ferent instruments, none reported subscales only). Of the 173
trials, 37 (21%, 95% CI 16% to 28%) speciﬁed QoL outcomes in
the protocol but remained unpublished after a median follow-up
of 11.6 years (range, 8.8–12.6 years), and 18 (10%, 95% CI 7%
to 16%) speciﬁed QoL outcomes but failed to report any QoL
outcomes in subsequent publications (Table 2).
risk factors for non-reporting of QoL outcomes
Using complete cases only, none of the independent factors we
explored (investigator sponsorship, sample size, trial discontinu-
ation, or single-centre status) was signiﬁcantly associated with
failure to report any QoL outcomes (Table 3). This ﬁnding was
conﬁrmed in a sensitivity analysis with the alternative outcome
‘failure to report QoL outcomes exactly as speciﬁed in protocol’
(supplementary Table 2, available at Annals of Oncology online).
When we used multiple imputations, trial discontinuation was sig-
niﬁcantly associated with failure to report any QoL outcome (OR
2.88, 95% CI 1.00–8.29) and failure to report QoL outcomes
exactly as speciﬁed in protocol (OR 3.20, 95% CI 1.07–9.64) (sup-
plementary Tables 3 and 4, available at Annals of Oncology online).
discussion
main ﬁndings
Approximately half of cancer RCTs speciﬁed QoL outcomes in
their protocols; however, only 20% reported any QoL data in
Table 2. Planning and reporting of QoL outcomes
Total (N = 173) Investigator-sponsored
(N = 86)
Industry-sponsored
(N = 87)
QoL specified in protocol 90 (52%) 47 (55%) 43 (49%)
Published 53 (31%) 27 (31%) 26 (30%)
QoL reported 35 (20%) 16 (19%) 19 (22%)
Instruments as specified 31 (18%) 16 (19%) 15 (17%)
Only one of two instruments 3 (2%) 0 3 (3%)
Two completely different instruments 1 (1%) 0 1 (1%)
QoL not reported 18 (10%) 11 (13%) 7 (8%)
Not published 37 (21%) 20 (23%) 17 (20%)
QoL not specified in protocol 83 (48%) 39 (45%) 44 (51%)
Published 55 (32%) 26 (30%) 29 (33%)
QoL not reported 55 (32%) 26 (30%) 29 (33%)
Not published 28 (16%) 13 (15%) 15 (17%)
QoL, quality of life.
Table 3. Risk factors for non-reporting of QoL outcomes
Univariable effect Multivariable effect
Odds ratio
(95% confidence interval)
P Adjusted odds ratio
(95% confidence interval)
P
Planned target sample sizea 0.98 (0.91–1.06) 0.63 1.00 (0.93–1.08) 0.95
Discontinued RCT (versus completed) 2.62 (0.95–7.20) 0.062 2.65 (0.93–7.52) 0.067
Single-centre status (versus multicentre) 1.48 (0.13–16.98) 0.75 1.16 (0.13–20.31) 0.71
Investigator sponsorship (versus industry) 1.66 (0.69–4.00) 0.26 1.56 (0.62–3.91) 0.34
Of the 90 RCT that pre-specified QoL outcomes, we excluded seven RCTs with unclear completion status (none of them reporting any QoL outcomes) thus
leaving 83 RCTs and a total of 48 events for analysis.
See supplementary Tables 1–3, available at Annals of Oncology online, for sensitivity analyses.
aIn increments of 100.
RCT, randomized clinical trial.
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associated publications. The main reason for the failure to report
QoL outcomes was non-speciﬁcation in the protocol (48%), fol-
lowed by non-publication of the trial (21%), and non-reporting of
QoL outcomes reported in protocols in subsequent publications
(10%). In other words, if QoL outcomes were speciﬁed at all,
most of them were not reported. Failure to report pre-speciﬁed
QoL outcomes was possibly associated with trial discontinuation
but not with sponsorship, sample size, or single-centre status.
strength and limitations
The data for the present study were collected as part of a large
international cohort involving six RECs that allowed us full access
to RCT protocols and ﬁled correspondence [12, 13]. As outlined
previously [19, 20]. Comparing protocols with subsequent publi-
cations is the most reliable method to evaluate the reporting of
RCTs. We identiﬁed corresponding publications by systematically
searching REC ﬁles, multiple electronic databases, and by con-
tacting trialists through the REC in charge [12]. We focused on
protocols that had been approved 10 or more years after REC
approval to minimize the number of on-going or unpublished
RCTs [13]. We involved only trained methodologists in data
abstraction and two oncologists who independently categorized
the patient populations regarding the intention of treatment.
Our study has limitations. Because we extracted a total of 1017
RCT protocols and corresponding publications for the main
project [13], we used single data extraction for 61% of cancer trial
protocols due to limited resources, thereby potentially introducing
extraction errors. However, we used pre-piloted extraction forms
with detailed written instructions, conducted formal calibration
exercises with all data extractors, and measured agreement between
independent data extractors from a random sample of protocols at
several points during the process. Agreement was good with no
more than two discrepancies in 30 extracted key variables [13].
We used a convenience sample of six RECs in three countries.
We cannot claim that these are representative for other RECs in
these or other countries; however, to our knowledge, they are
not in any way idiosyncratic.
We implicitly assumed that collection of QoL outcomes
would have been important in all included cancer trials. Most
trials from our sample included patients who were treated with a
palliative intention; evaluating the impact of experimental treat-
ments on QoL is more than appropriate in these settings. In
addition, we excluded dose-ﬁnding studies that typically do not
include QoL as an outcome. However, we acknowledge that
there may be instances where collection of QoL outcomes in
cancer patients may be less important, e.g. when treating acute
life-threatening conditions (six RCTs) or if the QoL outcomes
related to this intervention have been previously well described
(which is rather unlikely). We decided a priori to include any
QoL instrument at face value, which is irrespective of its validity
in a speciﬁc setting. We felt that further sub-division into vali-
dated, non-validated, and unclear would add an additional level
of complexity but would be unlikely to affect our conclusions.
Finally, we did not ask investigators for unreported study
results or the reasons why a study or a pre-speciﬁed outcome
was not published. Therefore, we could not investigate whether,
for example the level of statistical signiﬁcance inﬂuenced the
decision to report the outcome in the publication [17].
comparison with other studies
Our study conﬁrms the previously reported large extent of
under-reporting of RCT outcomes [17]. To our knowledge, this
is the ﬁrst study to assess planning of QoL outcomes in RCTs
protocols involving cancer patients and the subsequent con-
cordance of reporting.
We can only speculate about the reasons why investigators of
oncological studies initially plan to measure QoL but then often
do not report QoL outcome data. Earlier studies hypothesized
that investigators may encounter methodological difﬁculties
with analysing or interpreting QoL outcomes [21], or may dis-
trust the integrity of their QoL data due to inconsistent collec-
tion or substantial missingness of data [22]. It is unlikely that
investigator did not collect any data for the QoL outcomes that
they speciﬁed in the protocol; a recent survey of RCT investiga-
tors suggested that in only 13 of 419 RCTs (3%) investigators
did not collect data for pre-speciﬁed outcomes [23].
We assume that the most likely reasons for not reporting of
QoL outcomes in cancer RCTs are similar to those that have
been repeatedly identiﬁed by other studies: data for secondary
outcomes were not analysed after negative main results [23], or
ﬁndings might be inconclusive or unfavourable [17]. One
reason for inconclusive QoL results and subsequent non-publi-
cation may include premature trial discontinuation as suggested
by our regression analysis. Finally, the failure to report QoL out-
comes may also be motivated by reasons such as journal space
restrictions, data being perceived as uninteresting, or trialists’
lack of awareness of the implications [23, 24].
Our data did not support the ﬁnding of a smaller study (25
cancer RCTs) that cancer RCTs recruit more successfully than
other RCTs [25]. About a third of cancer RCTs were premature-
ly discontinued and 13% because of poor recruitment. These
proportions were similar to previously reported ﬁndings in
RCTs of all disciplines of which 28% were prematurely discon-
tinued and 11% due to poor recruitment [13].
implications
Failure to report pre-speciﬁed outcomes can seriously bias pub-
lished evidence [26], especially because positive ﬁndings are
more likely to be reported than negative ﬁndings [17]. For in-
stance, a meta-analysis of cancer trials suggested that adminis-
tration of erythropoiesis-stimulating agents prolonged survival,
while an updated individual patient data meta-analysis that
included previously unpublished outcome data showed no sig-
niﬁcant effect [27].
Given the importance of QoL outcomes for cancer patients and
the risk of bias introduced by selective reporting, we believe that the
oncology community should take action to address this problem.
A number of solutions are possible; one would be that journals
request protocols to accompany all manuscript submissions and
ensure concordance between planned and reported outcomes.
conclusion
Only ∼20% of cancer RCTs approved by RECs subsequently
reported QoL outcomes. Most cancer RCTs either never speci-
ﬁed QoL outcomes, did so but were never published, or failed
to report pre-speciﬁed QoL outcomes in their corresponding
publications. Consequently, highly relevant information is often
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unavailable to users of cancer research including cancer patients,
oncologists, and health policymakers.
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